SquidInSunglasses
Bluelighter
- Joined
- Dec 8, 2015
- Messages
- 1,511
Per this paper, the activation of microglia plays a role in dopamine-related neurotoxicity (the paper is specifically about meth, but the mechanisms involved should be general), and this activation can be inhibited by NMDA antagonists, which in turn prevents neurotoxic effects from occuring. However, since DXM is also a serotonin reuptake inhibitor, it is a risk if taken in combination with SSRIs or MDMA, due to the increased risk of serotonin syndrome (the combination with SSRIs is currently a concern, but MDMA would be a concern in the future). My question is, given that L-phenylalanine is easily available and acts as an NMDA antagonist at the glycine site, would it be usable as a neuroprotective agent?